Publications by authors named "H Pappot"
Background And Purpose: The gold standard when treating muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC), a procedure that holds the potential to affect the function of several pelvic organs, causing an impact on the patient's Quality of Life (QoL). Knowledge of the late effects following bladder cancer and treatment with RC is sparse. The aim is to describe the incidence of late effects and to investigate the impact on QoL.
View Article and Find Full Text PDFPurpose: This register-based study investigates the probability of a livebirth after cancer during the female reproductive age.
Methods: The study population, derived from the DANAC II cohort, included women aged 18-39 diagnosed with cancer between 1978 and 2016, matched with 60 undiagnosed women each from the general population. Primary outcome was a livebirth after cancer with follow-up until death, emigration, or end of follow-up.
Purpose: Remote symptom monitoring of patients with cancer has previously shown potential for improving clinical outcomes. This study aimed to evaluate the effects of remote symptom monitoring in patients with lung cancer after palliative induction treatment.
Methods: In a Danish multicenter randomized controlled trial, patients were randomly assigned 1:1 to remote symptom monitoring (intervention arm) added to standard of care versus standard of care (control arm).
Purpose: This study aimed to explore the thoughts and experiences of young men with cancer regarding the risk of infertility and the oncofertility counseling they received at diagnosis and during their cancer trajectory.
Methods: This qualitative study was conducted from October 2023 to February 2024 at the Copenhagen University Hospital-Rigshospitalet. Inclusion criteria were male adolescents and young adults with cancer aged 15-29 years.
Article Synopsis
- Metastatic urothelial carcinoma (mUC) has a poor prognosis, and the study focuses on Prostaglandin Reductase 1 (PTGR1), which is crucial for the effectiveness of acylfulven drugs for treating specific mUC patients with ERCC2 mutations.
- The study evaluated PTGR1 expression in untreated mUC patients using immunohistochemistry (IHC), RNA expression analysis, and targeted genomic panels to identify candidates for clinical trials and assess the potential of PTGR1 as a prognostic biomarker.
- Results indicated that 40% of tumors tested positive for PTGR1 via IHC, demonstrating high sensitivity and specificity in RNA expression analysis, which correlated with tumor mutations and overall